|
Name |
2,2,6-Trimethyl-1-oxaspiro[2.5]octan-4-one
|
Molecular Formula | C10H16O2 | |
IUPAC Name* |
2,2,6-trimethyl-1-oxaspiro[2.5]octan-4-one
|
|
SMILES |
CC1CCC2(C(=O)C1)C(O2)(C)C
|
|
InChI |
InChI=1S/C10H16O2/c1-7-4-5-10(8(11)6-7)9(2,3)12-10/h7H,4-6H2,1-3H3
|
|
InChIKey |
OFUGTKAUAMKFPM-UHFFFAOYSA-N
|
|
Synonyms |
17677-87-1; 2,2,6-Trimethyl-1-oxaspiro[2.5]octan-4-one; (R)-Pulegone Oxide; NSC316069; 2,2,6-TRIMETHYL-1-OXASPIRO[2.5]OCTAN-8-ONE; p-Menthan-3-one, 4,8-epoxy-, trans-; 2,2,6-Trimethyl-1-oxaspiro(2.5)octan-4-one; 1-Oxaspiro[2.5]octan-4-one, 2,2,6-trimethyl-, cis-; Pulegonepoxid; pulegone oxide; trans-Pulegone Oxide; NSC 316069; 1,1,6-trimethyl-2-oxaspiro[2.5]octan-8-one; SCHEMBL9445749; DTXSID20938851; NSC-316069; FT-0674153; A934024; 2,2,6-Trimethyl-1-oxaspiro[2.5]octan-4-one, cis; 1-Oxaspiro[2.5]octan-4-one, 2,2,6-trimethyl-, (3R,6R)-rel-
|
|
CAS | 17677-87-1 | |
PubChem CID | 330109 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 168.23 | ALogp: | 1.4 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 29.6 | Aromatic Rings: | 2 |
Heavy Atoms: | 12 | QED Weighted: | 0.52 |
Caco-2 Permeability: | -4.538 | MDCK Permeability: | 0.00002590 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.012 |
30% Bioavailability (F30%): | 0.016 |
Blood-Brain-Barrier Penetration (BBB): | 0.982 | Plasma Protein Binding (PPB): | 65.57% |
Volume Distribution (VD): | 1.428 | Fu: | 43.67% |
CYP1A2-inhibitor: | 0.069 | CYP1A2-substrate: | 0.744 |
CYP2C19-inhibitor: | 0.141 | CYP2C19-substrate: | 0.934 |
CYP2C9-inhibitor: | 0.049 | CYP2C9-substrate: | 0.216 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.451 |
CYP3A4-inhibitor: | 0.019 | CYP3A4-substrate: | 0.579 |
Clearance (CL): | 9.879 | Half-life (T1/2): | 0.801 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.297 |
Drug-inuced Liver Injury (DILI): | 0.829 | AMES Toxicity: | 0.778 |
Rat Oral Acute Toxicity: | 0.604 | Maximum Recommended Daily Dose: | 0.042 |
Skin Sensitization: | 0.1 | Carcinogencity: | 0.929 |
Eye Corrosion: | 0.017 | Eye Irritation: | 0.157 |
Respiratory Toxicity: | 0.588 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001341 | 0.500 | D0H1QY | 0.429 | ||||
ENC000481 | 0.364 | D0A2AJ | 0.246 | ||||
ENC002301 | 0.351 | D0U3GL | 0.243 | ||||
ENC005088 | 0.340 | D0S3WH | 0.243 | ||||
ENC001082 | 0.333 | D0V8HA | 0.235 | ||||
ENC000085 | 0.326 | D0K0EK | 0.233 | ||||
ENC005519 | 0.326 | D0K7LU | 0.231 | ||||
ENC002225 | 0.298 | D0D2VS | 0.227 | ||||
ENC003480 | 0.294 | D0G6AB | 0.224 | ||||
ENC002074 | 0.293 | D0G8BV | 0.218 |